Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA warns against purchasing Accutane online

Executive Summary

FDA launches a Web site March 28 to warn consumers about the dangers of purchasing the acne medication isotretinoin (Roche's Accutane and generics) online. The agency advises, "Buying this product over the Internet bypasses important procedures to ensure that patients can take this drug safely," and may result in patients receiving counterfeit products. Isotretinoin is legally available only through iPLEDGE, a restricted distribution and risk management system to ensure the drug is not prescribed to pregnant patients. However, implementation of the iPLEDGE program has been plagued with compliance issues (1"The Pink Sheet" Sept. 4, 2006, p.15)...

You may also be interested in...



Accutane iPLEDGE Program Glitches Continue Six Months After Launch – AADA

Implementation problems with the iPLEDGE pregnancy risk management program for the acne therapy isotretinoin (Roche's Accutane and generics) may be relieved by eliminating the mandatory one month hiatus between physician office visits, a study by the American Academy of Dermatology Association found

Cosmetic And Personal Care Trademark Review: 16 April

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

Health And Wellness Weekly Trademarks Review: 16 April

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS048202

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel